Navigation Links
Flu breakthrough: New drug developed to combat flu pandemic
Date:2/22/2013

The new drug has been proven to be effective in preventing the spread of different strains of influenza in laboratory models including resistant strains of the virus.

The breakthrough is the result of a global collaboration between scientists from CSIRO, the University of British Columbia and the University of Bath.

In order to infect cells, flu viruses bind onto sugars on the cell surface. To be able to spread they need to remove these sugars. The new drug works by preventing the virus from removing sugars and blocking the virus from infecting more cells. It is hoped the drug will also be effective against future strains of the virus.

According to the World Health Organisation, influenza kills approximately 500,000 people each year, with up to 2500 of those deaths occurring in Australia[1]. Costs to the Australian health care system are estimated to be more than A$85M, with more than 1.5 million work days lost annually

CSIRO scientist Dr Jenny McKimm-Breschkin, a researcher in the team that developed the first flu drug Relenza, said that understanding exactly how flu viruses become resistant to drugs has helped them to design a better flu drug.

"CSIRO researchers have shown that flu viruses continually mutate and some have become resistant to available treatments," Dr Jenny McKimm-Breschkin said.

"The new drug is effective against these resistant strains. As the site where the drug binds is found in all flu strains, the new drug is expected to be effective even against future flu strains.

"With millions of poultry currently infected with 'bird flu' globally, there are still concerns about its adaptation and potential to spread among humans, causing the next pandemic," she added.

Professor Steve Withers, University of British Columbia, has led the research team for the past seven years and said that although further studies are required to determine efficacy against a broader range of flu strains, the findings are extremely positive.

"Despite recent improvements in vaccine production, when a new strain of flu emerges it can take several months before vaccines are available to the public," Professor Steve Withers said.

"This antiviral drug would play an important role as the first line of defence in modulating disease severity and in controlling a pandemic while vaccines are prepared," he added.


'/>"/>

Contact: Angela Beggs
angela.beggs@csiro.au
61-395-452-977
CSIRO Australia
Source:Eurekalert

Related biology news :

1. Breakthrough: How salt stops plant growth
2. Research breakthrough: High brain integration underlies winning performances
3. University-developed omega-3-rich ground beef available soon
4. How the protein transport machinery in the chloroplasts of higher plants developed
5. High Brightness Tetrapod Quantum Dots Developed
6. Test developed to detect early-stage diseases with naked eye
7. New cranial neural crest cell line developed
8. Humanized mice developed at OHSU enable malaria research breakthrough at Seattle BioMed
9. New long-term antimicrobial catheter developed
10. Electronic nose prototype developed
11. Composite nanofibers developed by Penn scientists next chapter in orthopaedic biomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , ... from around the world, is pleased to announce the 2nd annual Precision Medicine ... This premier, online-only conference focused on the development and advancements in precision medicine. ...
(Date:2/22/2017)... MOINES, Iowa , Feb. 22, 2017 Origin (Origin ... agricultural biotechnology trait and seed provider, and Arcadia ... -based company that develops and commercializes agricultural productivity traits and nutritional ... a key corn biotechnology product developed in China ... of global regulatory trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
Breaking Biology Technology: